EUVIMEDEUVIMED entdecken
Crossref

The safety of pathogen‐reduced platelet transfusions in critically ill term and preterm neonates

Alexia D'hont iD, Ginette M Ecury-Goossen, Ruben J Overduin, Meindert E Manshande, Ashley J Duits iD

Vox Sanguinis · 2025

DOI: 10.1111/vox.13762 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vox Sanguinis, 2025. Verfasst von Alexia D'hont und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Subdivision of Neonatology, Curaçao Medical Center, Willemstad, Curaçao. Hauptthemen laut MEDLINE: Platelet Transfusion, Blood Safety. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Platelet transfusions carry an important risk of infection transmission. The Mirasol Pathogen Reduction Technology system for platelets uses riboflavin and UV light to introduce irreparable lesions into nucleic acids, thereby inhibiting pathogen replication and inactivating white blood cells. The objective of this study is to evaluate the safety of pathogen‐reduced platelet transfusions (PRPTs) in critically ill infants in a neonatal intensive care unit (NICU) in the Caribbean. Materials and Methods We conducted a descriptive retrospective study of the use of Mirasol PRPTs in patients admitted to the NICU of the general hospital in Curaçao from February 2016 to April 2023.

Results

A total of 208 PRPTs were administered to 46 patients (median [range] transfusions per patient: 3 [1–24]). Three patients were born term, and 43 were born preterm (median [range] gestational age: 27 4/7 weeks [24 6/7–36 6/7]). PRPTs were well‐tolerated and no complications occurred, especially no signs of haemolysis nor any signs of new infection within 24 h after transfusion. Twenty‐one of 46 patients (46%) died during their admittance. None of the deaths were deemed related to PRPT.

Conclusion

Mirasol PRPT appears to be safe for use in critically ill neonates, including extremely preterm neonates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Platelet TransfusionBlood SafetyHumansInfant, NewbornCritical IllnessRetrospective StudiesFemaleMaleInfant, PrematureIntensive Care Units, NeonatalRiboflavin

Stichwörter der Autor:innen

neonatepathogen reduced platelet transfusion

Substanzen

Riboflavin

Autor:innen und Institutionen

  • Department of Pediatrics, Subdivision of Neonatology, Curaçao Medical Center, Willemstad, Curaçao.
  • Department of Pediatrics, Antwerp University Hospital, Antwerp, Belgium.
  • Department of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Red Cross Blood Bank Foundation, Willemstad, Curaçao.

ORCID-Profile: Alexia D'hont, Ashley J Duits

Zitieren

APA

D'hont, A., Ecury-Goossen, G. M., Overduin, R. J., Manshande, M. E., & Duits, A. J. (2025). The safety of pathogen‐reduced platelet transfusions in critically ill term and preterm neonates. Vox Sanguinis. https://doi.org/10.1111/vox.13762

Vancouver

D'hont A, Ecury-Goossen GM, Overduin RJ, Manshande ME, Duits AJ. The safety of pathogen‐reduced platelet transfusions in critically ill term and preterm neonates. Vox Sanguinis. 2025. doi:10.1111/vox.13762

BibTeX
@article{Dhont2025,
  author = {D'hont, Alexia and Ecury-Goossen, Ginette M and Overduin, Ruben J and Manshande, Meindert E and Duits, Ashley J},
  title = {The safety of pathogen‐reduced platelet transfusions in critically ill term and preterm neonates},
  journal = {Vox Sanguinis},
  year = {2025},
  doi = {10.1111/vox.13762}
}
Kostenlos starten →